SFTSV感染周期和抗病毒药物的研究进展  

Research progress in life cycle and antiviral drugs for severe fever with thrombocytopenia syndrome virus

作　　者：刘铁柱[1] 梁米芳[1] 王世文[1] Liu Tiezhu;Liang Mifang;Wang Shiwen(NHC Key laboratory of Medical Virology and Viral Disease,National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China)

机构地区：[1]中国疾病预防控制中心病毒病预防控制所国家卫生健康委员会医学病毒和病毒病重点实验室,北京102206

出　　处：《中华实验和临床病毒学杂志》2022年第4期475-480,共6页Chinese Journal of Experimental and Clinical Virology

基　　金：复旦重点研发项目(2017YFA0205102-LMF(B))。

摘　　要：发热伴血小板减少综合征病毒(severe fever with thrombocytopenia syndrome virus,SFTSV)是一种蜱传的新型布尼亚病毒,在中国大别山地区被首次发现,临床上可以引起严重发热、血小板减少等症状,致死率可达10%~30%。目前,SFTSV的致病机理和感染机制尚不清楚,还没有针对该病毒的特效药物和疫苗。本文对SFTSV的入胞机制、膜融合、复制、装配和出芽过程进行了综述,总结了目前SFTSV相关的治疗性抗体和抗病毒药物的研究进展,以期为我国SFTSV的疫苗和抗病毒药物的研发提供参考。Severe fever with thrombocytopenia syndrome virus(SFTSV),is a tick-borne novel Bunyavirus,which was first discovered in the area of Dabie Mountain in China.It can cause severe fever and thrombocytopenia clinically,with a fatality rate of 10%to 30%.As the pathogenesis and infection mechanism of SFTSV are still unclear,there are no specific drugs and vaccines for SFTSV.In this paper,the mechanism of entry,replication,assembly and budding of SFTSV is reviewed,and the research progress of the treatment antibody and antiviral drugs of SFTSV is summarized,which will provide reference for the development of vaccines and antiviral drugs for SFTSV in China.

关 键 词：发热伴血小板减少综合征病毒 感染周期 抗病毒药物 

分 类 号：R373.3[医药卫生—病原生物学]